Drug Profile
Research programme: riburamycins - sanofi-aventis
Alternative Names: Fluorinated riburamycins research programme - sanofi-aventis; MraY inhibitors research programme - sanofi-aventis; Riburamycins research programme - sanofi-aventis; RU 75411Latest Information Update: 17 Aug 2007
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Enzyme inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 17 Aug 2007 No development reported - Preclinical for Bacterial infections in France (unspecified route)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form sanofi-aventis
- 22 Jan 2003 Preclinical trials in Bacterial infections in France (unspecified route)